Depomed Announces Closing of NUCYNTA Commercialization Agreement With Collegium Pharmaceutical
NEWARK, Calif., Jan. 10, 2018 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced the closing of its previously disclosed Commercialization Agreement (“Agreement”) for the U.S. rights to commercialize both NUCYNTA® Extended Release and NUCYNTA® …